ViiV Healthcare has filed a new drug application for cabotegravir-based two-drug HIV combination therapy
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, ViiV Healthcare(http://jointly announced that it has submitted anew drug(http://of theof the drug HIV combination therapy of Janssen's rilpivirine and ViiV's cabotegravir, thehttp://
FDAthis combination of two-drug HIV combination therapy is that it only needs one monthly injection to control HIV levels, to make it easier for patients and possibly improve compliance with medicationIf approved, it would be the first long-acting injection of two-drug HIV therapythis innovative long-acting HIV therapy is made up of cabotegravir developed by Rilpivirine and ViiVRilpivirine is an oral non-nucleoside retroviruse inhibitor (NNRTI) that has been approved in the United States and the European Union, while cabotegravir is an integrated enzyme inhibitor (INI) in the development phaseThis NDA is based on the results of a critical Phase 3 clinicaltrial(http://called ATLAS and FLAIR In both trials, which totalled more than 1,100 patients, rilpivirine/cabotegravir's monthly injection therapy had the same effect in suppressing viral levels compared to the standard one-day, three-drug combination therapy
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
